Vaccines Articles
The U.S. Food and Drug Administration has approved two new quadrivalent influenza vaccines (IIV4s).
A total of 4,659 adults aged 18 years or older were randomized to receive a single dose of inactivated quadrivalent influenza vaccine (IIV4) from one of three production lots or an inactivated trivalent influenza vaccine (IIV3) containing either a B/Victoria or B/Yamagata strain.
The first vaccine to protect children against the enterovirus 71, or EV71, that causes hand, foot and mouth disease has been developed by Chineses scientists at Beijing Vigoo Biological.
A recent study conducted at theUniversity of Alabama at Birmingham shows that the shingles vaccine appears to be safe and effective for those suffering from autoimmune diseases.
Initial results from a Phase 1 trial of the world’s first HIV vaccine has shown no adverse effects while significantly boosting immunity.
Researchers from Braasch Biotech in South Dakota have developed an obesity vaccine that stimulates the immune system to attack a hormone that promotes slow metabolism and weight gain.
A Phase II clinical trial that is testing the success of a pancreatic cancer vaccine is giving researchers hope that the treatment might be ready for wide distribution within the next couple of years.
The U.S. Food and Drug Administration has approved a new children’s vaccine that targets two common causes of bacterial meningitis.
A recent survey conducted by the U.S. Centers for Disease Control and Prevention shows that the number of provider sites participating inimmunization information systems has increased.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is recommending the expanded use of Pfizer’s Prevnar 13 vaccine.
Researchers at the Scripps ResearchInstitute in La Jolla, Calif., have developed a vaccine that may one day protect people against the addictive effects of nicotine.
The U.S. Food and Drug Administration has approved Fluarix Quadrivalent to immunize children ages 3 and older and adults against flu virus subtypes A and B.